Prenatal diagnostic tests carry up to a 1.5% risk of miscarriage. Non-invasive preclinical testing (NIPT) can provide parents with a risk rating before diagnostic tests are performed. PRENITA™ NIPT detects a range of aneuploidies and microdeletions from as early as 10 weeks. Speak to your health care provider to arrange your PRENITA™ NIPT.
Diagnostic prenatal tests, such as chorionic villus sampling and amniocentesis, are highly accurate but carry a 0.5 – 1.5 % risk of miscarriage. While maternal screening serum tests negate this risk, they typically carry a 5% chance of false-positive results.
PRENITA™ NIPT combines the merits of both techniques by negating the risk of miscarriage and reducing the chance of false-positive results.
With greater sensitivity and specificity of PRENITA™ NIPT, it is expected that the number of women undergoing unnecessary invasive testing will be reduced.
PRENITA™ NIPT is the most advanced, non-invasive prenatal screening test. With just 10 ml of maternal blood, we can analyse every chromosome to check for genetic conditions that could affect your baby’s health.
Following analysis, PRENITA™ NIPT provides a genetic score for the conditions tested:
There are several benefits of choosing PRENITA™ NIPT over other prenatal screening techniques, including:
✓ Early detection at 10 weeks
✓ Reduced risk of false positives
✓ Increased sensitivity and specificity
✓ Short turnaround time of 10 days
✓ Information on every chromosome
PRENITA™ NIPT can be offered to any expectant mother who wants information on the genetic condition of her baby, and is recommended to expectant mothers with:
✓ Advanced maternal age
✓ Positive maternal serum screen
✓ Abnormal ultrasound findings
✓ Positive personal or family history
If you are unsure whether PRENITA™ NIPT is right for you, or if you require further information, speak to your healthcare provider or download our FAQs document.